Voyager Therapeutics (VYGR) Equity Average (2016 - 2025)
Voyager Therapeutics (VYGR) has disclosed Equity Average for 11 consecutive years, with $208.0 million as the latest value for Q4 2025.
- Quarterly Equity Average fell 33.99% to $208.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $208.0 million through Dec 2025, down 33.99% year-over-year, with the annual reading at $247.9 million for FY2025, 7.51% down from the prior year.
- Equity Average hit $208.0 million in Q4 2025 for Voyager Therapeutics, down from $231.9 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $338.2 million in Q2 2024 to a low of $68.0 million in Q2 2022.
- Historically, Equity Average has averaged $187.5 million across 5 years, with a median of $196.9 million in 2023.
- Biggest five-year swings in Equity Average: plummeted 44.89% in 2022 and later soared 205.91% in 2023.
- Year by year, Equity Average stood at $91.2 million in 2021, then dropped by 23.91% to $69.4 million in 2022, then skyrocketed by 197.13% to $206.3 million in 2023, then surged by 52.73% to $315.0 million in 2024, then tumbled by 33.99% to $208.0 million in 2025.
- Business Quant data shows Equity Average for VYGR at $208.0 million in Q4 2025, $231.9 million in Q3 2025, and $258.3 million in Q2 2025.